The Endocannabinoid System as a Drug Target: A Comprehensive Review of Therapeutic Potential and Setbacks
A comprehensive review cataloging the therapeutic potential of endocannabinoid-targeting drugs across dozens of conditions, while acknowledging setbacks including rimonabant's psychiatric side effects and a FAAH inhibitor trial disaster.
Quick Facts
What This Study Found
This review provides a panoramic view of the endocannabinoid system as a therapeutic target, covering its role across a remarkable range of conditions: nausea, pain, inflammation, multiple sclerosis, anorexia, epilepsy, glaucoma, schizophrenia, cardiovascular disease, cancer, obesity, metabolic syndrome, Parkinson's, Huntington's, Alzheimer's, and Tourette's syndrome.
Approved drugs at the time included nabilone and dronabinol (for chemotherapy-induced nausea) and Sativex (for MS spasticity). Epidiolex was under investigation for childhood seizures.
The review also addressed major setbacks: rimonabant's psychiatric side effects leading to its withdrawal, and the serious adverse events in a clinical trial of a FAAH inhibitor that raised safety concerns for the entire class.
The authors identified key challenges: developing tissue-selective cannabinoid drugs, creating peripherally restricted compounds that avoid brain effects, and designing appropriate dosage forms.
Key Numbers
Approved drugs: nabilone, dronabinol (nausea), Sativex (MS spasticity). Under investigation: Epidiolex (seizures). Failed: rimonabant (obesity, psychiatric side effects), FAAH inhibitor (serious adverse events in trial). Dozens of potential therapeutic applications identified.
How They Did This
Comprehensive narrative review of the endocannabinoid system's therapeutic applications, covering approved drugs, drugs in development, and failed candidates across multiple disease areas.
Why This Research Matters
This review provides a snapshot of the cannabinoid therapeutics landscape at a pivotal moment, when both promise and peril were evident. Understanding both the successes and failures helps contextualize the ongoing effort to develop safe, effective cannabinoid medicines.
The Bigger Picture
The breadth of conditions potentially treatable through the endocannabinoid system is remarkable, but so are the challenges. The field needs to move beyond the all-or-nothing approaches of direct receptor agonists and antagonists toward more nuanced strategies like allosteric modulators, enzyme inhibitors, and peripherally restricted agents.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. The breadth of coverage necessarily limits depth in any one area. Rapidly evolving field means some information was already outdated at publication.
Questions This Raises
- ?Which of the many potential therapeutic applications will prove viable in clinical trials?
- ?Can tissue-selective cannabinoid drugs be developed to avoid systemic side effects?
- ?Will the setbacks with rimonabant and FAAH inhibitors ultimately be overcome?
Trust & Context
- Key Stat:
- Therapeutic potential identified across dozens of conditions, from cancer to neurodegeneration
- Evidence Grade:
- Broad narrative review providing comprehensive overview but without systematic search methodology.
- Study Age:
- Published in 2016. Epidiolex has since been FDA-approved, and several other cannabinoid drugs have advanced or failed in development.
- Original Title:
- Endocannabinoid System: A Multi-Facet Therapeutic Target.
- Published In:
- Current clinical pharmacology, 11(2), 110-7 (2016)
- Authors:
- Kaur, Rimplejeet, Ambwani, Sneha R, Singh, Surjit
- Database ID:
- RTHC-01192
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What diseases could be treated through the endocannabinoid system?
Research has identified potential therapeutic applications in pain, inflammation, epilepsy, cancer, obesity, multiple sclerosis, neurodegenerative diseases, psychiatric conditions, and many more, though most remain under investigation.
Why have some cannabinoid drugs failed?
The main setbacks have been psychiatric side effects from CB1 blockers (rimonabant) and serious adverse events in a FAAH inhibitor trial. Developing drugs that target specific tissues while avoiding brain effects remains a key challenge.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01192APA
Kaur, Rimplejeet; Ambwani, Sneha R; Singh, Surjit. (2016). Endocannabinoid System: A Multi-Facet Therapeutic Target.. Current clinical pharmacology, 11(2), 110-7.
MLA
Kaur, Rimplejeet, et al. "Endocannabinoid System: A Multi-Facet Therapeutic Target.." Current clinical pharmacology, 2016.
RethinkTHC
RethinkTHC Research Database. "Endocannabinoid System: A Multi-Facet Therapeutic Target." RTHC-01192. Retrieved from https://rethinkthc.com/research/kaur-2016-endocannabinoid-system-a-multifacet
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.